Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.
In this episode of the “CURE Talks Cancer” podcast, Dr. Dan Pollyea discusses the basics of AML, as well as treatment options currently available for patients.
Acute myeloid leukemia (AML), a blood cancer that starts in the bone marrow, accounts for almost 20,000 new cases of cancer, according to the American Cancer Society.
It is one of the most common types of leukemias in adults; however, the disease comprises only about 1% of all cancers.
There are a variety of treatment options available for patients with AML, with more clinical trials evaluating new therapies in the pipeline. In this episode of the “CURE talks Cancer” podcast, we spoke with Dr. Dan Pollyea, from the University of Colorado School of Medicine, about these treatment options.
